Skip to main content

N. Alejandro (Alex) Barbagelata

Adjunct Professor in the Department of Medicine
Medicine, Cardiology

Overview


Medical degree at the University of Buenos Aires. Residency/Cardiology Fellowship at the Sanatorio Guemes/Favaloro Foundation. Cardiac cath fellow at the Sanatorio Guemes. International Scholar in Artificial Organs at the Cleveland Clinic. Duke Clinical Research Institute research fellow.

Faculty member in the Cardiology Division at the University of Texas Medical Branch with the rank of Assoc Professor of Medicine as CCU and Cardiac Cath Lab attending (invasive cardiologist) on all type of cardiovascular diseases Director or Associated Dir of the Advanced Heart Failure that included devices such as aquapheresis, 2.5 impella, Cardiac Power, and surgical such as being part of the approval team for destination therapy on Heart Mate II. UNOS primary physician in the Heart Transplant program 2011-2013. Current Adj Ast Professor Medicine/Cardiology at Duke University, member of the Board of Directors of DUCCS (a Duke Clinical Research organization). Director of the Advanced Heart Failure Postgraduate Program at the Universidad Catolica Argentina (UCA). Staff member Interventional Cardiology service at the Instituto del diagnostico y tratamiento, Buenos Aires, Argentina. 

Research Interest in Acute Myocardial Infarction and Heart Failure, percutaneous and surgical devices in heart failure. Early identification of STEMI such as criteria's for MI in LBBB (http://en.wikipedia.org/wiki/Sgarbossa's_criteria), new descriptors in Q wave/non Q wave, use of telemedicine for timeliness reperfusion. Co-editor of the book on “prehospital Management of Acute Myocardial Infarction” Member of the Int. Speaker Bureau AHA. Published more than 60 peer articles and more than 100 hundred abstract and speaker in a number of Scientific Meetings.

Current Appointments & Affiliations


Adjunct Professor in the Department of Medicine · 2016 - Present Medicine, Cardiology, Medicine

Recent Publications


Efficacy of cardiac myosin activators compared to placebo in patients with heart failure and reduced ejection fraction: A systematic review and meta-analysis of randomized controlled trials.

Journal Article Heart Lung · 2026 BACKGROUND: Cardiac myosin activators (CMAs) have been explored as a potential therapy to enhance cardiac contractility in patients with heart failure with reduced ejection fraction (HFrEF). However, their effect on clinical outcomes, including mortality, ... Full text Link to item Cite

Atrial shunt therapy for heart failure: an update review.

Journal Article Heart Fail Rev · December 2, 2025 Interatrial shunt devices (IASDs) and implant-free strategies have emerged as novel approaches for heart failure (HF) management by mechanically unloading the left atrium (LA) to reduce left atrial pressure (LAP), a key driver of pulmonary congestion and e ... Full text Link to item Cite

Efficacy and safety of apixaban versus vitamin K antagonists in patients with heartmate 3 fully magnetically levitated left ventricular assist device: a comprehensive meta-analysis.

Journal Article J Thromb Thrombolysis · October 2025 BACKGROUND: Vitamin K antagonists (VKAs) are the first-line strategy for anticoagulation in patients with left ventricular assist devices (LVADs). Recently, the HeartMate 3 (HM3) LVAD, has shown lower thrombotic complications than previous technologies. Di ... Full text Link to item Cite
View All Publications

Education, Training & Certifications


University of Buenos Aires (Argentina) · 1982 M.D.